Stelis Biopharma and Pieris link up for novel Anticalin therapeutics in ophthalmology

Stelis Biopharma (formerly Agila Biotech), a subsidiary of India’s Strides Arcolab (BO: 532531), and privately-held German firm Pieris have initiated a long-term collaboration for clinical development and commercialization of multiple novel Anticalin-based protein therapeutics worldwide, primarily focusing on ophthalmology.

The alliance deploys the synergies of Pieris’ innovative drug discovery and early development capabilities with Stelis’ strong bio-manufacturing and clinical development expertise. Under the terms of the accord, Pieris will advance each collaborative program through in vivo proof of concept, at which stage Stelis will be responsible for drug manufacturing and advancing the molecule through a first-in-human clinical study. Following positive clinical data, the parties will co-develop programs under a joint venture.

Stelis attracting partners